Paclitaxel +\-tovecimig: COMPANION-002 ph2/3
➡️既往接受过治疗的 #BTC，无可靶向的基因组改变
➡️ORR 17.1% vs 5.3%；DCR 62% vs 37%
➡️mPFS 4.7 vs 2.6个月——PFS2 时观察到获益，同时需注意存在交叉治疗
➡️OS 无显著差异，但需注意存在交叉治疗
@myESMO #ESMO26 @OncoAlert
121 浏览 · 5 赞 · 4 转发 · 0 回复
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org来源：Grainne O'Kane · x.com